European Journal of Clinical Microbiology & Infectious Diseases最新文献

{"title":"Evaluation of a four-day incubation protocol for blood cultures: a quality improvement project.","authors":"Fatimah AlMutawa, Johan Delport","doi":"10.1007/s10096-025-05054-3","DOIUrl":"10.1007/s10096-025-05054-3","url":null,"abstract":"<p><p>Blood cultures are critical in diagnosing bloodstream infections and guiding the treatment of sepsis, which carries a significant mortality risk. Traditional blood culture protocols often recommend a five-day incubation period to ensure the recovery of clinically significant pathogens. However, recent evidence suggests that a shorter incubation period may be sufficient, potentially reducing laboratory workload and the recovery of contaminants.</p><p><strong>Methods: </strong>This quality improvement project was conducted to evaluate the performance of a four-day incubation protocol using the BD BACTEC automated blood culture system in a large academic center with over 1,000 beds, processing more than 70,000 blood culture requests annually. A retrospective analysis was performed on 71,862 blood cultures processed in 2022.</p><p><strong>Results: </strong>Results indicated that 99.2% of all positive cultures, including those in pediatric cases, were detected within four days, with a mean time to positivity of 23.97 h. Only 0.8% of blood cultures flagged positive after the four-day mark, and these were predominantly cases with previous positive cultures or repeat cultures that did not alter patient management.</p><p><strong>Conclusion: </strong>We conclude that a four-day incubation period is sufficient for the detection of clinically significant pathogens using the BD BACTEC system. This change not only optimizes laboratory operations by increasing capacity and reducing waste but also supports timely clinical decision-making.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"933-938"},"PeriodicalIF":3.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143381935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and prognostic insights into Chlamydia trachomatis in pediatric acute respiratory infections: evidence from targeted next-generation sequencing of 5,021 cases.","authors":"Chunyun Fu, Huan Zhang, Xiangjun Lu, Yanhua Feng, Lishai Mo, Junming Lu, Huiping Huang, Qiang Huang, Cuihong Lu, Wenting Tang, Ruting Chen, Silin Jiang, Ya Huang, Qifei Li, Jie Tan","doi":"10.1007/s10096-025-05049-0","DOIUrl":"10.1007/s10096-025-05049-0","url":null,"abstract":"<p><strong>Background: </strong>Chlamydia trachomatis (CT) is a major cause of respiratory tract infections in children. The primary objective of this research was to evaluate the infection status and clinical manifestations associated with C. trachomatis in these pediatric patients.</p><p><strong>Methods: </strong>From April 2021 to November 2023, a total of 5,021 hospitalized children with acute respiratory tract infections were collected at the Guangxi Maternal and Child Health Hospital. tNGS was used to detect pathogens in their respiratory samples.</p><p><strong>Results: </strong>Among the 5,021 hospitalized pediatric patients with acute respiratory tract infections, targeted next-generation sequencing (tNGS) detected C. trachomatis in 138 cases, with a detection rate of 2.75%. Among the 138 cases positive for C. trachomatis, 10 were identified as single C. trachomatis infection, while 128 cases involved co-infections with other pathogens. A total of 36 additional pathogens were detected in children with mixed Chlamydia trachomatis infections, with Pneumocystis jirovecii being the most frequently detected. In children with C. trachomatis infection, pulmonary consolidation and hypoxemia were the most commonly observed respiratory complications, whereas anemia and liver function impairment were the primary complications affecting other organ systems. The median duration of hospitalization for the 138 children was 8 days. Among the 138 children with C. trachomatis infection, 108 cases (78.26%) required respiratory support, and 11 cases (7.97%) required ICU admission.</p><p><strong>Conclusion: </strong>The detection rate of C. trachomatis among hospitalized pediatric patients with respiratory tract infections was 2.75%. This study delineates the clinical manifestations and infection patterns of C. trachomatis in Guangxi, China.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"867-875"},"PeriodicalIF":3.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Central-venous-catheter-related bloodstream infections in adult patients with sickle cell disease: a retrospective, two-centre study.","authors":"Matthieu Holub, David Lebeaux, Patrick Grohs, Laure Joseph, Olivier Pellerin, Geoffrey Cheminet, Najiby Kassis, Salomé Abdellaoui, Jacques Pouchot, Brigitte Ranque, Jean Benoit Arlet, Emmanuel Lafont","doi":"10.1007/s10096-024-05035-y","DOIUrl":"10.1007/s10096-024-05035-y","url":null,"abstract":"<p><strong>Purpose: </strong>Although catheter-related infections are the leading cause of bloodstream infections in patients with sickle cell disease (SCD), data are scarce in adult patients. The objectives of the present study were to describe central-venous-catheter-related bloodstream infections in patients with SCD and identify risk factors.</p><p><strong>Methods: </strong>We conducted a retrospective, observational study of adult patients with SCD diagnosed with central-venous-catheter-related bloodstream infections between 2011 and 2023 in two SCD reference centres. Each patient with SCD and a bloodstream infection related to a totally implantable venous access port was matched with two control patients with SCD and an infection-free totally implantable venous access port.</p><p><strong>Results: </strong>Thirty-five (6.6%) of the 534 patients experienced a total of 69 central-venous-catheter-related bloodstream infections. Concomitant vaso-occlusive crises were observed for 81.2% of the infections. The 30-day mortality rate was 2.8%, and the infection recurrence rate was 45.7%. We observed 26 totally implantable venous access port-related bloodstream infections in 19 patients, with an incidence rate of 0.31 per 1000 catheter-days. After adjustment, the frequency of hospital admission for a vaso-occlusive crisis (odds ratio (OR) [95% confidence interval (CI)] = 1.6 [1.2-2.4]) and the presence of a psychiatric comorbidity (19.8 [4.0-148.1]) remained significantly associated with totally implantable venous access port-related bloodstream infections. Suboptimal antibiotic levels were observed in five (39%) of the 13 patients having undergone therapeutic drug monitoring. The treatment failed in four (80%) of the five patients, who presented with glomerular hyperfiltration.</p><p><strong>Conclusion: </strong>A central-venous-catheter-related bloodstream infection is a severe complication in adult patients with SCD and is associated with psychiatric comorbidities and severe SCD.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"877-886"},"PeriodicalIF":3.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and risk factors of expatriates returning to Switzerland colonized at the intestinal level with multidrug-resistant Enterobacterales.","authors":"Edgar I Campos-Madueno, Claudia Aldeia, Marie C Roumet, Andreas Limacher, Parham Sendi, Andrea Endimiani","doi":"10.1007/s10096-025-05069-w","DOIUrl":"10.1007/s10096-025-05069-w","url":null,"abstract":"<p><p>Living in high-endemic regions increases the risk of intestinal colonization by multidrug-resistant Enterobacterales (MDR-Ent). This study investigated Swiss expatriates residing abroad (≥ 3 months) to assess their colonization status upon returning to Switzerland. Selective culture-based methods were implemented to detect third-generation cephalosporins- (3GC-R), carbapenems- (CR), and colistin-resistant (COL-R) strains. Whole-genome sequencing was used to characterize antimicrobial resistance genes, sequence type (ST), and phylogroup of MDR-Ent. Epidemiological data were analyzed using uni- and multivariable models to identify risk factors, providing crude and adjusted odds ratios (ORs). Among 196 participants living across Africa, Asia, the Americas, and Europe, the overall MDR-Ent colonization prevalence was 42.9%. Continent of residence emerged as a significant risk factor (p = 0.04) for colonization: Africa (adjusted OR = 3.4, 95% CI 1.0-11.0) and Asia (adjusted OR = 4.7, 95% CI 1.5-15.0). Extended-spectrum β-lactamase-producing Escherichia coli (Ec) was the most frequent isolated species (n = 107 out of 119 Ent). Most 3GC-R-Ec possessed bla_CTX-M genes (n = 89; 83.2%) and pandemic lineages were frequent (e.g., ST69 and ST131, n = 18). No CR-Ent were detected, but some COL-R strains (n = 18; of which 15 Ec) harbored the mcr-1.1 gene. Expatriates represent an understudied population at risk of MDR-Ent colonization. This population may contribute to the importation and potential dissemination of dangerous bacteria into low-prevalence countries, as shown in this Swiss study, warranting further investigation and surveillance.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"1007-1014"},"PeriodicalIF":3.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11947073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic epidemiology of vancomycin-resistant Enterococcus faecium in Eastern Denmark from 2020 to 2022, and identification of vanB Tn1549 insertion sites.","authors":"Maja Johanne Søndergaard Knudsen, Jose Alfredo Samaniego Castruita, Ingrid Maria Cecilia Rubin, Sarah Mollerup, Helle Krogh Johansen, Rasmus L Marvig, Karen Leth Nielsen, Barbara Juliane Holzknecht, Morten Hoppe, Michael Kemp, Henrik Westh, Mette Pinholt","doi":"10.1007/s10096-025-05091-y","DOIUrl":"https://doi.org/10.1007/s10096-025-05091-y","url":null,"abstract":"<p><strong>Background: </strong>We aimed to describe the genomic epidemiology of vancomycin-resistant Enterococcus faecium (VREfm) in Eastern Denmark from 2020 to 2022, identify and characterise the vanB Transposon 1549 (Tn1549) insertion sites among vanB VREfm clones and identify emerging VREfm clones.</p><p><strong>Methods: </strong>We analysed all VREfm from our routine diagnostic sequencing during the study period. Using the Seqsphere + v.8.2.0 software (Ridom GmbH, Münster, Germany, ( http://www.ridom.de/seqsphere ), minimum spanning trees were created to visualise clusters. Tn1549 insertion sites were determined by in silico PCR. Nanopore sequencing was performed to assemble the regions surrounding Tn1549, which helped determine the insertion site locations.</p><p><strong>Results: </strong>We included 2,437 isolates in the study. A total of 463 isolates carried vanA, 1,963 isolates carried vanB, and 11 isolates carried both genes. Of all isolates carrying vanB, 254 isolates had the Tn1549 inserted in the araA2 gene, 1,604 in the sir2 gene, and 116 in neither the araA2 nor sir2 genes. We identified eight chromosomal insertion sites other than in the araA2 and sir2 genes. Three isolates carried the Tn1549 on plasmids. No emerging clones were found.</p><p><strong>Results: </strong>We have described the genomic epidemiology during the study period and identified ten chromosomal Tn1549 insertion sites.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Salvage therapy of complicated Candida albicans spondylodiscitis with Rezafungin.","authors":"Nina Grasselli Kmet, Roberto Luzzati, Jacopo Monticelli, Stella Babich, Jacopo Conti, Stefano Di Bella","doi":"10.1007/s10096-025-05117-5","DOIUrl":"https://doi.org/10.1007/s10096-025-05117-5","url":null,"abstract":"<p><p>Invasive fungal infections, particularly those caused by Candida species, represent an increasing cause of hospital-related morbidity and mortality. Most commonly Candida spp. is the causative agent of candidemia and invasive candidiasis. In this report we present a complex case of Candida albicans spondylodiscitis, successfully treated with rezafungin, a new echinocandin suitable for weekly outpatient administration. This case illustrates the first documented use of rezafungin in an outpatient setting for C. albicans spondylodiscitis, demonstrating its potential in managing complex fungal infections.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a point-of-care test for the simultaneous detection of respiratory syncytial virus and IL-33 as a disease biomarker in children.","authors":"Felipe A Cancino, Daniela Moreno-Tapia, Mariana Ríos, Yaneisi Vázquez, Ana María Contreras, Marcela Ferrés, Dona Benadof, Ana María Guzmán, Francisca Valdivieso, Mauricio Farfán, Eduardo Espejo, Angélica Domínguez, Pablo J Bertrand, Valentina Gutiérrez, Hernán F Peñaloza, Pablo A González, Alexis M Kalergis, Susan M Bueno","doi":"10.1007/s10096-025-05104-w","DOIUrl":"https://doi.org/10.1007/s10096-025-05104-w","url":null,"abstract":"<p><strong>Purpose: </strong>The human respiratory syncytial virus (hRSV) is a leading cause of acute respiratory disease in children under 5 years of age. hRSV infection is associated with significant morbidity and mortality and represents a substantial economic burden for public health systems worldwide. Early and accurate diagnosis is critical for effective patient management, but current diagnostic tools, such as RT-qPCR, require specialized equipment and personnel. Further, currently available methods do not provide information regarding the prognosis of the disease caused by hRSV. Given this scenario, we aimed at generating and pre-validating a new rapid diagnosis test based on an immunochromatographic strip (ICS) to be used as a point-of-care (POC) test capable of simultaneously detecting the phosphoprotein P of hRSV (P-hRSV) and a biomarker of disease severity, interleukin-33 (IL-33) in nasal swabs.</p><p><strong>Methods: </strong>Monoclonal antibodies against P-hRSV and IL-33 were produced and incorporated into an ICS. The 20-min rapid diagnostic test was evaluated and validated with recombinant proteins, virus-infected cells, viral dilutions, and hRSV-positive and negative clinical samples. Sensitivity and specificity were assessed.</p><p><strong>Results: </strong>The ICS detected 103 pg of P-hRSV and as low as 187 PFUs of hRSV. Regarding recombinant IL-33, the ICS detected as low as 780 pg. The test strip exhibited high specificity, distinguishing hRSV from other respiratory viruses, including influenza and human metapneumovirus. Additionally, IL-33 was detected in some non-RSV infections.</p><p><strong>Conclusions: </strong>The data obtained supports the feasibility of a combined rapid test detecting simultaneously hRSV and IL-33, which can be useful as a POC test for screening severe cases of hRSV in primary care settings and emergency rooms.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological and clinical profiles of respiratory syncytial virus infections in hospitalized children: a retrospective cohort study utilizing targeted next-generation sequencing.","authors":"Chunyun Fu, Jialing Ruan, Lishai Mo, Jiangyang Zhao, Junming Lu, Ya Huang, Xuehua Hu, Qiang Huang, Yanhua Feng, Wenting Tang, Ning Zhu, Cuihong Lu, Xiangjun Lu, Ruting Chen, Guangbing Liu, Huiping Huang, Qifei Li, Jie Tan","doi":"10.1007/s10096-025-05112-w","DOIUrl":"https://doi.org/10.1007/s10096-025-05112-w","url":null,"abstract":"<p><strong>Background: </strong>Respiratory syncytial virus (RSV) is a significant cause of respiratory infections in children. Currently, there is limited literature on the clinical use of pathogen-targeted sequencing technologies and the systematic analysis of RSV infections in hospitalized children. The primary objective of this research was to evaluate the infection status and clinical manifestations associated with RSV in these pediatric patients.</p><p><strong>Methods: </strong>Between July 2021 and November 2023, 5,021 children hospitalized due to respiratory infections or associated complications were enrolled at the Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region. Targeted next-generation sequencing (tNGS) was used to detect pathogens in their respiratory samples. Subsequently, the clinical data of children infected with RSV were systematically evaluated.</p><p><strong>Results: </strong>Of the 5,021 children hospitalized with respiratory infections, RSV was detected in 1,080, yielding a detection rate of 21.5%. Among RSV-positive patients, only 8.6% (93/1080) experienced single infections, while the majority, 91.4% (987/1080), had co-infections with other pathogens. Among the observed infection patterns, RSV-viral-bacterial co-infection was the most prevalent, occurring in 524 cases (48.5%), followed by RSV-viral co-infection in 141 cases (13.1%). Among children with RSV co-infections, 43 additional microorganisms were detected, with cytomegalovirus, Haemophilus influenzae, and Streptococcus pneumoniae being the most prevalent. Of the 1,080 children diagnosed with RSV, 172 (15.9%) required ICU admission for monitoring. The median duration of hospitalization for the 1080 children diagnosed with RSV infection was 8 days. Of these, 1025 (94.9%) patients recovered and were discharged following treatment, while 54 (5.0%) of the patients' family members requested voluntary discharge due to unsatisfactory outcomes or other reasons. Unfortunately, one child (0.1%) died despite receiving intensive medical treatment.</p><p><strong>Conclusion: </strong>Due to the high incidence of RSV infections and associated ICU admissions, there is a critical need for effective vaccine development to protect infants and children. This study presents a comprehensive analysis of hospitalized pediatric patients with RSV, examining infection patterns, clinical manifestations, laboratory findings, imaging characteristics, complications, and prognosis.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and safety of cefiderocol treatment in patients with Gram-negative bacterial infections in Spain in the early access programme: results of the PERSEUS study.","authors":"Julian Torre-Cisneros, Benito Almirante, Carmen De La Fuente Martos, Pedro Rascado, Miguel Salavert Lletí, Miguel Sánchez-García, Alex Soriano, Maria Cruz Soriano-Cuesta, A Javier Gonzalez Calvo, Andreas Karas, Jessica Sarda, Stefano Verardi, Ricard Ferrer","doi":"10.1007/s10096-025-05108-6","DOIUrl":"https://doi.org/10.1007/s10096-025-05108-6","url":null,"abstract":"<p><strong>Purpose: </strong>We assessed the effectiveness and safety of cefiderocol in patients with Gram-negative bacterial infections, excluding Acinetobacter spp., in the early access programme (EAP) in Spain.</p><p><strong>Methods: </strong>The retrospective, multicentre PERSEUS study (2018-2022) enrolled hospitalised patients with serious Gram-negative infections, except Acinetobacter spp., who received first-time cefiderocol for ≥ 72 h following requests through the EAP. Clinical cure at end of treatment, all-cause mortality at Day 28, cefiderocol use, and adverse drug reactions (ADRs) were the key outcomes.</p><p><strong>Results: </strong>Overall, 261 patients were eligible for analysis. Median (interquartile range) age was 61 (49-68) years, 202 (77.4%) were male and 165 (63.2%) were in the intensive care unit. The most frequent diagnoses were respiratory tract infection (47.9%), intra-abdominal infection (14.6%), and urinary tract infection (14.6%). The median (IQR) duration of cefiderocol treatment was 10 (7-14) days. Overall, the clinical cure rate was 80.5% (210/261) and the 28-day mortality rate was 21.5% (56/261). In patients with Pseudomonas aeruginosa infection (66.7% [n = 174], including 73 [42%] with metallo-β-lactamases), the clinical cure rate was 84.5% (147/174) and the 28-day mortality was 17.2% (30/174). Logistic regression analysis showed that prior antibiotic treatment for > 7 days (OR 0.19, 95% CI 0.05-0.56) and mechanical ventilation (OR 0.32, 95% CI 0.15-0.67) were independent negative predictive factors for clinical cure. ADRs occurred in seven patients, six events resolved, and one was fatal (toxic epidermal necrolysis).</p><p><strong>Conclusions: </strong>Cefiderocol is a valuable option in the treatment of serious Gram-negative bacterial infections, particularly for those caused by P. aeruginosa.</p><p><strong>Clinicaltrials: </strong>GOV: NCT05789199 (Registration date: 16 February 2023).</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cefiderocol treatment for patients infected by Stenotrophomonas maltophilia, Burkholderia cepacia complex and Achromobacter spp.: subgroup analysis from the PERSEUS study.","authors":"Julian Torre-Cisneros, Ricard Ferrer, Carmen De La Fuente Martos, Jessica Sarda, A Javier Gonzalez Calvo, Stefano Verardi, Andreas Karas, Alex Soriano","doi":"10.1007/s10096-025-05109-5","DOIUrl":"https://doi.org/10.1007/s10096-025-05109-5","url":null,"abstract":"<p><strong>Purpose: </strong>This subgroup analysis of the PERSEUS study aimed to describe the effectiveness of cefiderocol treatment in the early access programme in Spain in patients infected by Stenotrophomonas maltophilia, Burkholderia cepacia complex (Bcc) or Achromobacter species.</p><p><strong>Methods: </strong>In the retrospective, observational, multicentre PERSEUS study in Spain, the effectiveness and safety of cefiderocol treatment administered for at least 72 h up to 28 days in patients infected by Gram-negative bacteria, except Acinetobacter spp., in the early access programme was investigated. Patient demographics and baseline clinical characteristics, cefiderocol use, clinical cure at end of treatment, all-cause mortality at Day 28 were the main outcomes.</p><p><strong>Results: </strong>A total of 20 patients had S. maltophilia infections, and 14 patients had other rare glucose non-fermenters (Bcc 8, Achromobacter spp. 5, Ralstonia mannitolilytica 1). The median (interquartile range [IQR]) age was 60.5 (48.0-65.5) years and 49.5 (33.0-59.0) years for patients with S. maltophilia and other rare non-fermenters, respectively. The majority of patients had respiratory tract infections (S. maltophilia 55%; other rare non-fermenters 71.4%), and median (IQR) duration of cefiderocol treatment was 10.0 (6.5-13.5) days and 8.0 (6-14) days, respectively. Clinical cure rates were 70%, 62.5% and 80.0% for patients with S. maltophilia, Bcc and Achromobacter spp., respectively. Corresponding 28-day all-cause mortality rates were 30.0%, 37.5% and 40.0%, respectively. One patient with R. mannitolilytica had clinical cure and survived to Day 28.</p><p><strong>Conclusions: </strong>Cefiderocol is an important addition to the limited treatment options for patients infected by these rare glucose non-fermenting Gram-negative bacteria.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov: NCT05789199 (Registration date: 16 February 2023).</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143700030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}